Howland Capital Management LLC Increases Position in Novartis A G (NVS)

September 16, 2018 - By Ann Prendergast

Novartis AG (NYSE:NVS) Logo

Howland Capital Management Llc increased its stake in Novartis A G (NVS) by 23.97% based on its latest 2018Q2 regulatory filing with the SEC. Howland Capital Management Llc bought 40,438 shares as the company’s stock rose 11.40% with the market. The institutional investor held 209,120 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $15.80M, up from 168,682 at the end of the previous reported quarter. Howland Capital Management Llc who had been investing in Novartis A G for a number of months, seems to be bullish on the $194.22B market cap company. The stock decreased 0.09% or $0.08 during the last trading session, reaching $85.22. About 1.33 million shares traded. Novartis AG (NYSE:NVS) has declined 1.50% since September 16, 2017 and is downtrending. It has underperformed by 17.12% the S&P500.

Howland Capital Management Llc, which manages about $1.25 billion and $1.25 billion US Long portfolio, decreased its stake in Vanguard Bd Index Fd Inc (BSV) by 86,645 shares to 55,249 shares, valued at $4.32 million in 2018Q2, according to the filing.

More notable recent Novartis AG (NYSE:NVS) news were published by: which released: “Top Analyst Upgrades and Downgrades: Baker Hughes, CBS, Generac, Halliburton, Nike, PG&E, Snap, Tesla …” on September 11, 2018, also with their article: “Novartis streamlining as US prices decline” published on September 04, 2018, published: “NHS England to offer Novartis’ CAR-T Kymriah” on September 05, 2018. More interesting news about Novartis AG (NYSE:NVS) were released by: and their article: “Novartis’ Gilenya shows treatment benefit in young people with MS” published on September 13, 2018 as well as‘s news article titled: “Conatus: Elucidating The Upcoming Binary Catalyst For Emricasan” with publication date: September 11, 2018.

Novartis AG (NYSE:NVS) Ratings Coverage

Among 5 analysts covering Novartis (NYSE:NVS), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Novartis had 5 analyst reports since May 25, 2018 according to SRatingsIntel. HSBC downgraded the stock to “Hold” rating in Tuesday, May 29 report. On Thursday, July 19 the stock rating was upgraded by Barclays Capital to “Equal-Weight”. On Friday, May 25 the stock rating was upgraded by Credit Suisse to “Neutral”. The firm earned “Buy” rating on Monday, September 10 by Bank of America. Citigroup upgraded the stock to “Buy” rating in Tuesday, September 11 report.

Novartis AG (NYSE:NVS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: